On April 21, 2016, Judge Eldon E. Fallon, the federal judge supervising and overseeing the centralized litigation against Janssen, Johnson & Johnson and Bayer over Xarelto, issued an order scheduling the depositions of plaintiffs and defense witnesses. The court is overseeing the discovery necessary to develop several “bellwether” trials in order to evaluate the strength and weaknesses of the cases brought against the pharmaceutical giants and to determine the values of certain harms and injuries. [Read more…]
Xarelto Release in 2011 Leads to Thousands of Serious Injuries by 2014, Consolidated Lawsuits Through 2016-2017
Xarelto Multidistrict Litigation – Case Update
The Xarelto multidistrict bellwether litigation is moving forward in the U.S. District Court in the Eastern District of Louisiana. The Court asked the parties in late December 2015 to select pool cases, which selection was completed January 11, 2016. The Court also requested that the chosen cases reflect multiple Xarelto injury categories, including gastrointestinal bleed and gi bleeding, brain bleeding events, hemorrhages, and hemorrhagic strokes. The Court is expected to select additional cases for inclusion originating in multiple states. The first trials are set for early February 2017 in Louisiana, with subsequent trials to occur in Mississippi and Texas in April and May 2017.
Patients charge that Xarelto is a dangerous and defective drug because in certain patients it triggers uncontrolled bleeding and other life-threatening complications. Xarelto was approved in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use has been expanded, including to patients with irregular heartbeats or facing a strong likelihood of blood clots in the legs or lungs.